JP2016116527A5 - - Google Patents

Download PDF

Info

Publication number
JP2016116527A5
JP2016116527A5 JP2016023490A JP2016023490A JP2016116527A5 JP 2016116527 A5 JP2016116527 A5 JP 2016116527A5 JP 2016023490 A JP2016023490 A JP 2016023490A JP 2016023490 A JP2016023490 A JP 2016023490A JP 2016116527 A5 JP2016116527 A5 JP 2016116527A5
Authority
JP
Japan
Prior art keywords
antibody
treatment
mammalian
fibrosis
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016023490A
Other languages
English (en)
Japanese (ja)
Other versions
JP6223483B2 (ja
JP2016116527A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016116527A publication Critical patent/JP2016116527A/ja
Publication of JP2016116527A5 publication Critical patent/JP2016116527A5/ja
Application granted granted Critical
Publication of JP6223483B2 publication Critical patent/JP6223483B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016023490A 2010-07-15 2016-02-10 カドヘリン−11のec1ドメインを標的とするヒト化抗体ならびに関連組成物および方法 Expired - Fee Related JP6223483B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36469810P 2010-07-15 2010-07-15
US61/364,698 2010-07-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013519849A Division JP5886283B2 (ja) 2010-07-15 2011-07-15 カドヘリン−11のec1ドメインを標的とするヒト化抗体ならびに関連組成物および方法

Publications (3)

Publication Number Publication Date
JP2016116527A JP2016116527A (ja) 2016-06-30
JP2016116527A5 true JP2016116527A5 (enExample) 2016-09-08
JP6223483B2 JP6223483B2 (ja) 2017-11-01

Family

ID=44630044

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013519849A Expired - Fee Related JP5886283B2 (ja) 2010-07-15 2011-07-15 カドヘリン−11のec1ドメインを標的とするヒト化抗体ならびに関連組成物および方法
JP2016023490A Expired - Fee Related JP6223483B2 (ja) 2010-07-15 2016-02-10 カドヘリン−11のec1ドメインを標的とするヒト化抗体ならびに関連組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013519849A Expired - Fee Related JP5886283B2 (ja) 2010-07-15 2011-07-15 カドヘリン−11のec1ドメインを標的とするヒト化抗体ならびに関連組成物および方法

Country Status (21)

Country Link
US (2) US8940300B2 (enExample)
EP (2) EP2593128B1 (enExample)
JP (2) JP5886283B2 (enExample)
KR (1) KR101695056B1 (enExample)
CN (2) CN103153331B (enExample)
AU (1) AU2011279044B2 (enExample)
BR (1) BR112013001062A2 (enExample)
CA (1) CA2805112A1 (enExample)
DK (1) DK2593128T3 (enExample)
ES (1) ES2665317T3 (enExample)
HR (1) HRP20180563T1 (enExample)
HU (1) HUE038000T2 (enExample)
IL (2) IL224186A (enExample)
LT (1) LT2593128T (enExample)
MX (1) MX343376B (enExample)
NO (1) NO2593128T3 (enExample)
PT (1) PT2593128T (enExample)
RS (1) RS57215B1 (enExample)
SG (1) SG187097A1 (enExample)
SI (1) SI2593128T1 (enExample)
WO (1) WO2012009631A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010007551A (es) * 2008-01-11 2010-11-30 Synovex Corp Antagonistas de la cadherina-11 y metodos para el tratamiento de trastornos inflamatorios de las articulacion.
CA2805112A1 (en) 2010-07-15 2012-01-19 Synovex Corporation Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
HUE037811T2 (hu) 2011-10-28 2018-09-28 Prothena Biosciences Ltd Alfa-szinukleint felismerõ humanizált antitestek
CN108517010A (zh) 2012-01-27 2018-09-11 普罗典娜生物科学有限公司 识别α-突触核蛋白的人源化抗体
CN104203280A (zh) * 2012-03-27 2014-12-10 诺华股份有限公司 纤维化的治疗
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
BR112015023086A2 (pt) * 2013-03-15 2017-11-21 Abbvie Biotechnology Ltd anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença.
CN105377892A (zh) * 2013-03-15 2016-03-02 艾伯维生物技术有限公司 抗cd25抗体及其用途
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US11097005B2 (en) * 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
CN113912725B (zh) * 2016-01-09 2024-03-08 嘉立医疗科技(广州)有限公司 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
FI3830119T3 (fi) * 2018-08-01 2026-01-23 Imcheck Therapeutics Anti-btn3a-vasta-aineita ja niiden käyttö syövän tai infektiosairauksien hoitamisessa
CN113072633B (zh) * 2021-04-21 2022-11-15 湖北医药学院 Cdh11截短型变体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2084987C (en) 1990-06-11 2007-02-13 Gilead Sciences, Inc. Nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
DK0835939T3 (da) 1990-06-28 2006-03-13 Sanofi Aventis Deutschland Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
JP3560252B2 (ja) * 1992-08-28 2004-09-02 アベンティス ファーマ株式会社 骨関連カドヘリン様タンパク質およびその製造法
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
US6638911B1 (en) 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
AU759144B2 (en) 1998-05-05 2003-04-03 Adherex Technologies Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
US6787136B1 (en) 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
DE60044904D1 (de) 1999-09-03 2010-10-14 Brigham & Womens Hospital Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien
US20040110755A1 (en) 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
CA2506037A1 (en) 2002-11-14 2004-06-10 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
WO2006089397A1 (en) 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Methods for treating arthritis using triheterocyclic compounds
MX2010007551A (es) 2008-01-11 2010-11-30 Synovex Corp Antagonistas de la cadherina-11 y metodos para el tratamiento de trastornos inflamatorios de las articulacion.
EP2245067A2 (en) * 2008-02-11 2010-11-03 Novartis AG Methods of using cadherin 11 (cdh11) antagonists
CA2805112A1 (en) 2010-07-15 2012-01-19 Synovex Corporation Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods

Similar Documents

Publication Publication Date Title
JP2016116527A5 (enExample)
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
JP2018127467A5 (enExample)
JP2018504907A5 (enExample)
EA201791093A1 (ru) Антитела к cd47, способы и применение
AU2018256498A1 (en) Antibodies to amyloid beta
JP2014205674A5 (enExample)
MX2018015584A (es) Anticuerpos anti-pd-l1 y usos de los mismos.
JP2011157378A5 (enExample)
EP4276114A3 (en) Cd20 binding single domain antibodies
JP2016502515A5 (enExample)
JP2014534239A5 (enExample)
PE20150002A1 (es) Anticuerpos anti-fcrn
JP2014509837A5 (enExample)
JP2016515522A5 (enExample)
JP2014502955A5 (enExample)
JP2014503189A5 (enExample)
EA201890315A1 (ru) Молекулы антител, связывающие cd22
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
JP2014237714A5 (enExample)
MX395257B (es) Anticuerpos para cd40.
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion